Background: Protein C (PC) and protein S (PS) determination is part of the thrombophilia investigation in patients with idiopathic venous thromboembolism (VTE). Based on scarce evidence it is a common notion that PC and PS levels decrease during the acute phase of VTE, necessitating delay of testing and temporary transition from warfarin to low molecular weight heparin. We have previously demonstrated that an abnormal PC or PS result determined within 24 hours of VTE diagnosis and before the initiation of warfarin needs to be repeated for confirmation ≥3 months after starting treatment and ≥14 days after stopping anticoagulation therapy. In the current study, we sought to show that normal PC and PS values determined during the acute phase of VTE are not false negatives.
Introduction
Venous thromboembolism (VTE) is a common event, often precipitated by surgery, immobility or active malignancy [1] . Many cases, however, have no clear precipitant and are defined as idiopathic VTE [2] [3] [4] . The diagnostic work up for these patients includes testing for inherited and acquired hypercoagulable conditions, usually including functional quantitative assays for proteins C and S, and antithrombin, as well as testing for lupus anticoagulant, antiphospholipid antibodies, activated protein C resistance (with or without genetic testing for Factor V Leiden) and determination of the G20210A Prothrombin gene mutation [4] . Although from a practical standpoint this group of tests is most conveniently performed at the time of acute VTE diagnosis, concerns have been raised in the literature by studies suggesting that acute VTE may alter the levels of coagulation factors and lead to false positive (i.e. low) results.
Specifically, it is commonly believed that proteins C and S levels are markedly decreased during the initial phases of VTE, presumably secondary to consumption of these factors, thus rendering them uninterpretable. The evidence that protein C and S levels are decreased during an acute VTE event is based on a study by D' Angelo et al [5] . This was a small series of 8 patients and only reported a lower mean protein C and S level and not the proportion of patients who had an abnormal result. Historically, some consider that protein C and S can also be falsely elevated on the basis of being acute phase reactants though there is no documented evidence to substantiate this claim. Thus, the idea that these levels could not be accurately measured during an acute event has since been incorporated into medical dogma without being further validated [2] [3] [4] [6] [7] [8] [9] . Given the fact that these proteins are vitamin K dependant, late testing requires temporary interruption of oral anticoagulant therapy for at least 10 days and, in some cases, bridging anticoagulation with alternative agents such as low molecular weight heparin (LMWH) with the inherent costs and inconvenience.
Our group previously published data on 254 patients with acute VTE in whom proteins C and S were determined within 24 hours of diagnosis before the initiation of oral anticoagulation [10] . Abnormal results were repeated at least 3 months after starting treatment and at least 14 days after stopping anticoagulant therapy. This study identified that the initial false positive rate for all protein C and protein S tests was only 2.2% and almost 98% of patients had correct results as assessed at diagnosis. A criticism of this study was that we did not repeat the normal results to ensure that these were not false negatives. In the current study we sought to verify patients with initially normal protein C and S determinations were, in fact, true normals by repeating their testing after anticoagulant therapy was discontinued.
Methods

Patients
We studied consecutive patients referred to the outpatient thromboembolism clinics at a university hospital with a diagnosis of acute symptomatic VTE objectively confirmed by previously described criteria [11, 12] All patients were at least 18 years old. Exclusion criteria were: previous venous thromboembolic events, therapy with low molecular weight heparin for >48 h prior to testing, abnormal baseline international normalized ratio or activated partial thromboplastin time (aPTT), active malignancy, VTE secondary to transient risk factor, pregnancy, presentation in the first six weeks postpartum, known chronic liver disease (defined as persistent elevation above normal levels of alanine aminotransferase or gamma glutamyl transferase) and oral anticoagulant therapy (warfarin) in the previous 2 weeks.
Thrombophilia Testing
Samples for thrombophilia testing were drawn prior to the initiation of oral anticoagulant therapy and within 24 h of diagnosis of venous thromboembolism for all patients. Blood samples were collected in 0.109 M (3.2%) sodium citrate tubes (Becton_Dickinson, NJ, USA). Plasma was obtained and samples were spun at 2000 g for 20 minutes twice at 20°C and then frozen at -70°C and tested in batches on a weekly basis. Protein C was measured on an ACL 9000 Coagulometer (Instrumentation Laboratories, Lexington, MD, USA) using IL Test ProClot (Instrumentation Laboratory) reagent. Protein S was measured on an ACL 3000 Coagulometer by the method of IL-Test protein S (Instrumentation Laboratory). The IL Test ProClot kit is a functional clotting protein C assay, based on the prolongation of the aPTT in the presence of activated protein C. The IL Test protein S kit is a functional clot based assay of free protein S. If a patient's initial testing of protein C or protein S were normal, the results were repeated after at least 6 months of anticoagulation therapy provided the patient had discontinued warfarin for at least 14 days. Patients who had initially abnormal tests were excluded from this study. At the time of study our laboratory normal range for protein C was 0.72-1.23 U/ml and the normal range for protein S was 0.60-1.60 U/ml. The previously published study used the same methods for PC and PS determination as the current study.
Statistical analysis
The proportion of patients who tested abnormal on the second test was determined and confidence intervals for proportions were determined by the Wilson's score method [13] using OpenEpi version 2.3 [14] . For comparison purposes data from the previous study was included and analyzed in the same way. Comparison between groups was done using χ 2 tests with 2-sided p-values < 0.05 considered to be statistically significant. A post-hoc analysis to determine the appropriateness of our sample to detect the observed proportion of false positive results on repeat testing showed that a sample size of 100 would be adequate to detect a 3.7% upper confidence bound at the 97.5% level of significance assuming a true sample proportion of 0.
Results
Ninety-nine patients with normal protein C and S determinations during the acute phase of VTE diagnosis were included in the study. There were 47 men and 52 women with a median age of 56 years (range 21-87). 50 patients had a diagnosis of deep vein thrombosis, 45 had a diagnosis of pulmonary embolism and 4 had concomitant deep vein thrombosis and pulmonary embolism. All patients had idiopathic VTE events. On repeat testing after anti-coagulant therapy discontinuation, none of the 99 patients had an abnormal result of either protein C or S (0%, 95% CI 0-3.7%) ( Table 1) . Data from our previous study on patients with initially abnormal protein C and S determination was then used for comparison. Among patients who initially had abnormally low results, 40% (95%CI 35.4-84.8%) were confirmed to have low protein C and 63.6% (95%CI 16.8-68.7%) low protein S on repeated testing (Table 1) . The difference of proportions between groups was statistically significant (χ 2 p-value < 0.001).
Discussion
Thrombophilia screening, including protein C and S determinations is an important part of the diagnostic investigation for idiopathic VTE in order to determine etiology, duration of anticoagulation, and to guide family testing [7, 8, 15] . It is widely believed that assays for natural coagulation inhibitors cannot be performed during the acute phase of VTE due to a consumptive decrease in protein C and S leading to false positive testing. This assumption is based on the study by D' Angelo et al that identified a mean decrease in protein S activity in patients with acute VTE before warfarin therapy [5] . This transient state of acquired protein S deficiency was thought to be a result of increase in C4bBP levels secondary to inflammation. The study only examined 8 patients and provided only a mean protein S level rather than showing the proportion of patients that had a level below the reference range. The authors of this study commented that these results would need to be repeated before concluding that acute VTE falsely lowers levels of protein S. These results have not been replicated in any further studies and, to our knowledge, the only other studies investigating this issue are our previous study in 2006 and this follow up study.
Our previous study in 254 patients with acute VTE showed that 91% of patients had normal protein C and S levels and among those with abnormal initial tests 4/12 and 6/12 were proven to have PC and PS deficiency at a later date. This figure resulted in a sensitivity of 100% and specificity of 97% and 98% respectively with the caveat that patients with an initial normal test were not retested at a later date therefore we could not be sure of possible missed false negatives. The current study shows that our previous assumptions are correct and PC and PS testing can be done at the time of an acute VTE event with a high degree of specificity and sensitivity. Assuming a pre-test probability of 2% the negative likelihood ratio for PC testing is 0 (95% CI, 0%-3%) and for PS testing is 0 (95% CI, 0%-2%).
There is no indication from this series of patients that acute VTE alters the levels of protein C or S enough to affect the diagnosis of coagulation factor deficiency. Whereas genetic tests such as Factor V Leiden and the G20210A prothrombin gene variant can be tested at any time, coagulometric assays (such as protein C and S) cannot be performed in patients anticoagulated with vitamin K antagonists. Therefore, patients with normal protein C or S levels at the time of diagnosis can be effectively ruled out as having deficiency of these proteins and can therefore avoid the expense and inconvenience of repeat testing during VKA therapy interruption.
In conclusion, our current study in combination with our previous results show that testing protein C and S levels during the acute diagnosis of VTE is a valid approach. We suggest that thrombophilia testing be per- 
